EligibleTrials

Clinical trials recruiting for Rectal Cancer Patients

8
Recruiting trials
1
US states with sites
5
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 1Phase 2 5Phase 3 1Not applicable 2

Drugs and treatments being studied

InterventionTrials
BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)1
Chemoradiation + EBRT Boost1
Chemoradiation + HDRBT Boost1
PD-1 inhibitor based immunotherapy1
Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles1
lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy1
mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group1
mFOLFOX regimen neoadjuvant therapy group1

Where trials are recruiting (top US states)

StateRecruiting trials
Texas1

Top cities

Dallas, Texas 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Rectal Cancer Patients often also study these conditions. Each links to its own recruiting-trial list.

Colorectal cancer 1359Rectal Cancer (Stage III) 7Targeted Therapy 8Rectal Cancer Stage II 5Rectal cancer 152Rectal Adenocarcinoma 23Organ Preservation 3Immunotherapy 40Chemoradiotherapy 6

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Rectal Cancer Patients trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.